{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:36:20Z","timestamp":1792528580124,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"DOI":"10.1007\/s00115-026-01995-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:08:08Z","timestamp":1783577288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Das wachsende Problem des nichtmedizinischen Gebrauchs von medizinischem Cannabis","The increasing problem of the nonmedical use of medical cannabis"],"prefix":"10.1007","author":[{"given":"N.","family":"Scherbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.drugalcdep.2010.02.017","volume":"110","author":"SJ Adamson","year":"2010","unstructured":"Adamson\u00a0SJ, Kay-Lambkin\u00a0FJ, Baker\u00a0AL, Lewin\u00a0TJ, Thornton\u00a0L, Kelly\u00a0BJ, Sellman\u00a0JD (2010) An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend 110:137\u2013143","journal-title":"Drug Alcohol Depend"},{"key":"1995_CR2","unstructured":"Bundesgesundheitsministerium (2025) https:\/\/www.Bundesgesundheitsministerium.de\/presse\/pressemitteilungen\/medizinal-cannabisgesetz-kabinett-pm-08-10-25.html"},{"key":"1995_CR3","unstructured":"Bundesopiumstelle (2026) https:\/\/www.bfarm.de\/DE\/Bundesopiumstelle\/_FAQ\/Medizinisches-Cannabis\/MedCan-Einfuhr-Ausfuhr\/faq-liste.html?nn=471310"},{"issue":"11","key":"1995_CR4","first-page":"186","volume":"120","author":"P Cremer-Schaeffer","year":"2023","unstructured":"Cremer-Schaeffer\u00a0P, Hennig\u00a0B, Schmidt-Wolf\u00a0G, Marschall\u00a0U, Petzke\u00a0F, H\u00e4user\u00a0W (2023) Prescriptions of Cannabinoid Drugs, 2019\u20132022. Dtsch Arztebl Int 120(11):186\u2013187","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"1995_CR5","first-page":"338","volume":"121","author":"P Cremer-Schaeffer","year":"2024","unstructured":"Cremer-Schaeffer\u00a0P, Langer\u00a0S (2024) The Prescribing of Cannabis Drugs to Self-Payers. Dtsch Arztebl Int 121(10):338\u2013339","journal-title":"Dtsch Arztebl Int"},{"key":"1995_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111263","volume":"257","author":"D Dawson","year":"2024","unstructured":"Dawson\u00a0D, Stjepanovi\u0107\u00a0D, Lorenzetti\u00a0V, Cheung\u00a0C, Hall\u00a0W, Leung\u00a0J (2024) The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis. Drug Alcohol Depend 257:111263","journal-title":"Drug Alcohol Depend"},{"key":"1995_CR7","unstructured":"DGPPN (2026) Evaluation des Konsumcannabisgesetzes: Vorl\u00e4ufige Daten erlauben keine Entwarnung. https:\/\/www.dgppn.de\/aktuelles\/stellungnahmen-und-positionen\/ekocan.html"},{"key":"1995_CR8","unstructured":"GKV-Arzneimittel-Schnellinformation (2019) Sonderbeilage Cannabis. https:\/\/www.gkv-gamsi.de\/suche\/suche?query=cannabis"},{"key":"1995_CR9","first-page":"61","volume-title":"Therapie psychischer Erkrankungen \u2013 State of the Art","author":"E Gouzoulis-Mayfrank","year":"2025","unstructured":"Gouzoulis-Mayfrank\u00a0E, Scherbaum\u00a0N (2025) Drogenabh\u00e4ngigkeit. In: Voderholzer\u00a0U, Hohagen\u00a0F (Hrsg) Therapie psychischer Erkrankungen \u2013 State of the Art, 20.\u00a0Aufl. Urban & Fischer, M\u00fcnchen Jena, S\u00a061\u201379","edition":"20"},{"key":"1995_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00406-024-01880-2","volume":"275","author":"E Hoch","year":"2024","unstructured":"Hoch\u00a0E, Volkow\u00a0ND, Friemel\u00a0CM, Lorenzetti\u00a0V, Freeman\u00a0TP, Hall\u00a0W (2024) Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. Eur Arch Psychiatry Clin Neurosci 275:281\u2013292","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1995_CR11","doi-asserted-by":"publisher","unstructured":"Manthey J, Jacobsen B, Kalke J, Kraus L, Radas S, Schranz A,\u2026,Schreier S (2025) Evaluation des Konsumcannabisgesetzes (EKOCAN): 1. Zwischenbericht. https:\/\/doi.org\/10.25592\/uhhfdm.17993","DOI":"10.25592\/uhhfdm.17993"},{"key":"1995_CR12","doi-asserted-by":"publisher","unstructured":"Manthey J, Kalke J, Kraus L et\u00a0al. (2026). Evaluation des Konsumcannabisgesetzes (EKOCAN): 2. Zwischenbericht. https:\/\/doi.org\/10.25592\/uhhfdm.18530","DOI":"10.25592\/uhhfdm.18530"},{"key":"1995_CR13","first-page":"625","volume":"122","author":"S Olderbak","year":"2025","unstructured":"Olderbak\u00a0S, Hollweck\u00a0R, Krowartz\u00a0EM, M\u00f6ckl\u00a0J, Hoch\u00a0E (2025) Konsum psychoaktiver Substanzen in Deutschland. Dtsch Artebl Int 122:625\u2013631","journal-title":"Dtsch Artebl Int"},{"key":"1995_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2215-0366(26)00015-5","volume":"13","author":"J Wilson","year":"2026","unstructured":"Wilson\u00a0J, Dobson\u00a0O, Langcake\u00a0A, Mishra\u00a0P, Bryant\u00a0Z, Leung\u00a0J, Dawson\u00a0D, GrahamM\u00a0M, Teesson\u00a0M, Freeman\u00a0TP, Hall\u00a0W, Chan\u00a0GCK, Stockings\u00a0E (2026) The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry 13:304\u2013315","journal-title":"Lancet Psychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-01995-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:36:55Z","timestamp":1784029015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-01995-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":14,"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-01995-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.\u00a0Scherbaum und U.\u00a0Bonnet geben an, dass kein Interessenkonflikt besteht. K.\u00a0M\u00fcller-Vahl erhielt finanzielle Unterst\u00fctzung von Studien durch das BMBF, Almirall, Abide Therapeutics, CannaXan, und Therapix Biosiences. Sie erhielt Honorare (Advisory Board, Vortragst\u00e4tigkeit) von Firmen, die medizinisches Cannabis herstellen oder vertreiben, wie Avextra, Aurora, Becanex, Canopy, Cansativa, Canymed, Four20 pharma, Sanity Group, Schurer Pharma & Kosmetik, Tilray, Trias Pharma, oder deren Interessen vertreten z.\u202fB. Arbeitsgemeinschaft Cannabis als Medizin, Branchenverband Cannabiswirtschaft e.\u202fV., Bundesverband pharmazeutischer Cannabinoidunternehmen. Sie ist Redaktionsmitglied der Zeitschriften \u201eCannabis and Cannabinoid Research\u201c und \u201eMedical Cannabis and Cannabinoids\u201c.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}